Study to Evaluate the Safety and Efficacy of Treatment with NLM-001 before Standard Chemotherapy plus Zalifrelimab in Patients with Advanced Pancreatic Cancer
Researchers are conducting an early-stage study (Phase I) to investigate a new treatment for advanced pancreatic cancer. This treatment involves a drug called NLM-001, given before standard chemotherapy, and also includes another drug called Zalifrelimab. The main goals are to check if this new combination is safe for patients and to see how well it works against the cancer. This type of study helps scientists understand new medicines better before they can be used more widely. It's open to adults aged 18 and over, and anyone can take part, regardless of gender. The study aims to find better ways to help people living with advanced pancreatic cancer.
At a glance
What is this study about?
This research study is about finding new ways to treat advanced pancreatic cancer. Pancreatic cancer can be very challenging to treat, and doctors are always looking for more effective options. This particular study is testing a new drug called NLM-001. It's being given before patients receive their regular chemotherapy, and it's also combined with another medication called Zalifrelimab. The idea is to see if this new combination can be safer and more effective than current treatments.
This is an early-stage study, often called a 'Phase I' study. This means it's one of the first times this new treatment combination is being tested in people. The main focus at this stage is to make sure the treatment is safe and to find the right dose. Researchers will also be looking closely to see if there are any signs that the treatment is helping to fight the cancer. They are trying to understand how the body reacts to these new medicines.
By taking part in studies like this, volunteers help scientists learn important information that could lead to new and improved treatments for pancreatic cancer in the future. Every step in this research process is vital to help people live longer and have a better quality of life.
Key takeaways
- This is an early-stage study (Phase I) for advanced pancreatic cancer.
- It tests a new drug (NLM-001) combined with standard chemotherapy and Zalifrelimab.
- The main goals are to check safety and see how well the new treatment works.
- Open to adults aged 18 and over, both men and women.
- Participation involves clinic visits, assessments, and close medical monitoring.
Who may be eligible?
To be considered for this study, you must be an adult aged 18 years or older. There is no upper age limit, meaning older adults are also welcome to take part if they meet other health requirements. Both men and women are able to join the study.
Because this is a medical study, there will be other important health checks to make sure the treatment is suitable and safe for you. These might include specific tests related to your pancreatic cancer, your overall health, and any other medical conditions or medicines you are currently taking. These checks are put in place to protect your safety and to make sure the study results are clear.
It's important to remember that meeting the basic age and gender requirements doesn't automatically mean you can join. A doctor involved in the study will need to review your full medical history and carry out some tests to confirm if this study is right for you. They will explain everything clearly.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have advanced pancreatic cancer?
- Are you able to attend regular hospital or clinic appointments?
- Are you willing to follow a specific treatment plan?
- Do you currently live in the UK?
What does participation involve?
If you decide to take part in this study, you will likely have several visits to the clinic or hospital. These visits will involve various assessments, such as physical examinations, blood tests, and possibly scans, to monitor your health and how the treatment is affecting you. You will receive the new treatment called NLM-001, followed by your standard chemotherapy, and the drug Zalifrelimab, all given according to a specific schedule decided by the study doctors.
Your medicine will be provided as part of the study, and the medical team will keep a close eye on you for any side effects or changes to your health. After your main treatment period, there will be follow-up visits. These are important for doctors to continue monitoring your health and the long-term effects of the treatment.
The total length of time you will be involved in the study will depend on the treatment plan and follow-up requirements, but the study team will explain the expected duration clearly before you make any decisions.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is the new drug NLM-001 for?
NLM-001 is a new drug being tested to see if it can help treat advanced pancreatic cancer, especially when combined with other existing treatments.
What does 'Phase I study' mean?
'Phase I' means this is one of the first times this new treatment combination is being tested in people. The main goals are to check its safety and find the right dose.
Who can join this study?
This study is open to adults aged 18 and older, regardless of whether they are male or female. You'll also need to meet other health requirements discussed by the study doctor.
Will I still get my usual chemotherapy?
Yes, this study involves taking NLM-001 before standard chemotherapy, plus another drug called Zalifrelimab. So, you would still receive chemotherapy as part of the study treatment.
Can I stop being part of the study if I want to?
Yes, you have the right to leave the study at any time, for any reason, and it will not affect your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.